<i>Mycobacterium bovis</i>BCG–Associated Osteomyelitis/Osteitis, Taiwan

Li-Min Huang, Shin Yi Wang, Nan Chang Chiu, Yhu Chering Huang, Wen Li Lin, Fu Yuan Huang, Ching Chuan Liu, Tzou Yien Lin, Meng Chin Lin, Ren Bin Tang, Hsin Chi

doi:10.3201/eid2103.140789

To the Editor: Thirty-eight patients with Mycobacterium bovis BCG–associated osteomyelitis/osteitis, including 8 who were previously reported (1), were identified during Taiwan’s vaccine injury compensation program during 1989–2012; a total of 30 (79%) patients applied for compensation during 2009–2012 (Figure). In Taiwan, a laboratory program to differentiate BCG from other species of the M. tuberculosis complex, using a kit for the Tokyo-172 vaccine strain spoligotyping, was established in 2004 (1). Since 2008, the isolated extrapulmonary tuberculosis strains and pathologic specimens collected from children <5 years of age have been sent to the national reference mycobacterial laboratory for BCG detection (2). The detected incidence of BCG osteitis/osteomyelitis increased from 3.68 cases per million vaccinations during 2002–2006 to 30.1 per million during 2008–2012.

<i>Mycobacterium bovis</i>BCG–Associated Osteomyelitis/Osteitis, Taiwan

Search this article

Description

Journal

Keywords

Details 詳細情報について

Export

Report a problem